ORAL DRUG DELIVERY ARTICLES
Need A Drug Delivery Conversation Starter? Try Target Product Profile
In this article, Chief Editor Tom von Gunden explores the need for and existence of cross-functional communication during drug product development and delivery device selection. He consults industry veterans with experience in various formulation or delivery roles at GSK and Merck. They identify the Target Product Profile (TPP) as the core concept guiding collaboration.
ORAL DRUG DELIVERY RESOURCES
-
Explore key considerations to successfully bridge from initial concept of pediatric program design and formulation development strategies into later stages of development and through to commercialization.
-
Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive.
-
Careful selection of appropriate excipients and delivery technologies is key to the design of modified release (MR) formulations fulfilling specific performance requirements.
-
The support of an experienced CDMO is critical to overcoming complexity when working with highly potent APIs and when solving solubility challenges.
-
Improve upstream media for bioavailability and foam stability, downstream buffers for purification, and the formulation and final fill drug product stability with this highly interdisciplinary process.
-
With a focus on the sustained and controlled drug delivery segment of the pharmaceutical market, learn about technology platforms, support services, and sustainable solutions.
-
Discover how applied rigorous characterization standards and expert knowledge of critical water activity enabled the isolation of a previously undiscovered and uncharacterized polymorph.
ORAL DRUG DELIVERY SOLUTIONS
-
Multiparticulates enable tailored drug release with improved flexibility, dose accuracy, and patient convenience, leveraging technologies like Diffucaps® for customized profiles including immediate, delayed, extended, and pulsatile delivery.
-
As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation.
-
Learn what oral modified-release (MR) dosage forms can offer and why they continue to rise in popularity.
-
Adare Pharma Solutions provides end-to-end CDMO services for oral solid dose drugs, enabling efficient development, manufacturing, and packaging with advanced technologies and global scale.
-
Battelle, a leading nonprofit in applied science and technology, drives innovation in national security, healthcare, environment, and education while managing research labs and advancing critical discoveries.
-
A new six-phase assessment process simplifies regulatory approval for generic drug-device combination products, reducing costs and timelines while maintaining safety, effectiveness, and substitutability with reference-listed drugs.
-
AustinPx offers integrated GMP manufacturing services for oral dosage forms with a full complement of analytical development and testing capabilities.
-
This comprehensive suite of services encompasses the entire spectrum of user research, starting from the conceptualization of study designs to meticulous data analysis and comprehensive reporting.
-
Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.
-
Nanoform’s award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology is a bottom-up nanoparticle engineering approach that enables the creation of API nanoparticles and can unlock the full therapeutic potential of small molecule drugs.